Akeso

This study tests two experimental drugs, AK109 and AK104, with or without chemotherapy, in people with advanced stomach or gastroesophageal junction cancer that has not responded to first-line treatment. The goal is to see if the combination can shrink tumors or slow disease prog…

This phase 3 trial tests whether the immunotherapy drug AK104 (Cadonilimab) given before and after surgery works better than standard chemotherapy for people with a specific type of colon cancer (MSI-H/dMMR). About 386 adults with stage II or III colon cancer that can be removed …

This study tests whether adding the experimental drug AK112 to standard chemotherapy (nab-paclitaxel) helps people with advanced triple-negative breast cancer live longer without their cancer growing. About 416 adults with inoperable or metastatic disease will receive either AK11…

This study tests whether adding extra drugs to a standard chemo-and-immunotherapy regimen can better control extensive-stage small cell lung cancer. About 180 adults who have not had prior treatment will be randomly assigned to one of three groups, each receiving the drug ivonesc…

This study tests whether a new drug called AK112, combined with chemotherapy, works better than the standard treatment (bevacizumab plus chemotherapy) for people with metastatic colorectal cancer that has spread. About 560 adults aged 18 to 75 who have not had prior treatment for…

This study is testing whether combining two experimental drugs (AK119 and AK112) is safe and can shrink tumors in people with advanced solid tumors that have stopped responding to standard treatments. About 87 adults aged 18 to 75 will participate. The goal is to find the best do…

This study tests whether adding the drug cadonilimab to standard chemotherapy before surgery helps people with a certain type of esophageal cancer. About 90 adults with resectable (removable) tumors will be randomly assigned to get either the new combo or chemo alone. The goal is…

This study tests whether adding ivonescimab to standard chemotherapy (docetaxel) helps adults with advanced non-small cell lung cancer whose disease has worsened after prior immunotherapy. About 536 participants will receive either the combination or a placebo plus chemotherapy. …

This early-phase study tests a new drug called AK146D1 in 200 people with advanced solid tumors that have stopped responding to standard treatments. The drug is designed to attach to two targets on cancer cells to deliver a powerful anti-cancer agent. The main goals are to check …

This study tests a new drug called AK112, alone or with other treatments, for people with advanced liver cancer that has not responded to standard therapy. The first part checks safety and the best dose, while the second part compares the drug's effectiveness against another appr…

This study tests whether adding the drug cadonilimab to standard chemotherapy (SOX) before and after surgery helps people with stomach or gastroesophageal junction cancer live longer without the cancer coming back. About 760 participants will receive either cadonilimab or a place…

This study tests two experimental drugs, AK130 and AK112, for people with advanced biliary tract cancer (a type of bile duct cancer) that has not responded to other treatments. The first part checks safety and the right dose, while the second part sees if the combination can shri…

This study tests whether a new drug called AK112 can help prevent lung cancer from coming back in people with limited-stage small cell lung cancer who have finished chemotherapy and radiation. About 560 participants will receive either AK112 or a placebo. The goal is to see if th…

This early-stage study tests a new drug called AK138D1 in up to 200 people with advanced solid tumors that haven't responded to standard treatments. The main goals are to check the drug's safety and find the best dose. Researchers will also look for signs that the drug can shrink…

This study tests whether a combination of two drugs, AK130 and AK112, can help people with advanced pancreatic cancer that has not responded to up to two prior treatments. The trial will enroll 160 participants and measure how many patients see their tumors shrink or stop growing…

This study tests a combination of two experimental drugs (AK104/AK112 and TT-00420) in 100 adults with advanced liver cancer that cannot be treated with surgery. The goal is to see if the drugs can shrink tumors and control the disease. Participants must not have had prior cancer…

This study tests whether adding the drugs ivonescimab and AK117 to standard chemotherapy helps people with metastatic pancreatic cancer live longer. About 999 adults aged 18-75 who have not had prior treatment for their advanced cancer will be randomly assigned to receive either …

This study is for people with advanced stomach cancer who have already been treated with the drug cadonilimab in a previous clinical trial. The goal is to collect long-term information, such as how long patients live, to better understand the drug's lasting effects. No new treatm…